Anabolic and andogenic activity of 19-norandrostenedione after oral and subcutaneous administration-Analysis of side effects and metabolism

Toxicology Letters

Volumn 188, Issue 2, 2009, Pages 137-141

  Parr, M K ^b   Laudenbach Leschowsky, U ^a   Höfer, Nicola ^a   Schanzer W ^b   Diel, P ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Anabolic steroid; Doping; Metabolism; Nandrolone; Norandrostenedione; Prohormone; Skeletal muscle

Indexed keywords

ESTR 4 ENE 3,17 DIONE; NANDROLONE; 19-NORANDROSTENEDIONE; ANABOLIC AGENT; ANDROGEN; ANDROSTENEDIONE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; HEART WEIGHT; LEVATOR ANI MUSCLE; LIVER WEIGHT; MALE; MASS FRAGMENTOGRAPHY; MUSCLE GROWTH; MUSCLE MASS; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE; RAT; SEMINAL VESICLE; SERUM; SKELETAL MUSCLE; WEIGHT REDUCTION; ANIMAL; BLOOD; BODY WEIGHT; DOSE RESPONSE; DRUG EFFECT; METABOLISM; ORAL DRUG ADMINISTRATION; ORGAN SIZE; SUBCUTANEOUS DRUG ADMINISTRATION; WISTAR RAT;

RATTUS;

ADMINISTRATION, ORAL; ANABOLIC AGENTS; ANDROGENS; ANDROSTENEDIONE; ANIMALS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, SUBCUTANEOUS; MALE; ORCHIECTOMY; ORGAN SIZE; RATS; RATS, WISTAR;

EID: 67349268429     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.03.024     Document Type: Article

References (23)

1. Boada L.D., Zumbado M., Torres S., Lopez A., Diaz-Chico B.N., Cabrera J.J., and Luzardo O.P. Evaluation of acute and chronic hepatotoxic effects exerted by anabolic-androgenic steroid stanozolol in adult male rats. Arch. Toxicol. 73 8-9 (1999) 465-472
2. De Cock K.J., Delbeke F.T., Van Eenoo P., Desmet N., Roels K., and De Backer P. Detection and determination of anabolic steroids in nutritional supplements. J. Pharm. Biomed. Anal. 25 5-6 (2001) 843-852
3. Diel P., Friedel A., Geyer H., Kamber M., Laudenbach-Leschowsky U., Schanzer W., Thevis M., Vollmer G., and Zierau O. Characterisation of the pharmacological profile of desoxymethyltestosterone (Madol), a steroid misused for doping. Toxicol. Lett. 169 1 (2007) 64-71
4. Diel P., Friedel A., Geyer H., Kamber M., Laudenbach-Leschowsky U., Schänzer W., Schleipen B., Thevis M., Vollmer G., and Zierau O. The prohormone 19-norandrostenedione displays selective androgen receptor modulator (SARM) like properties after subcutaneous administration. Toxicol. Lett. 177 3 (2008) 198-204
5. Friedel A., Geyer H., Kamber M., Laudenbach-Leschowsky U., Schänzer W., Thevis M., Vollmer G., Zierau O., and Diel P. 17beta-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties. Toxicol. Lett. 165 2 (2006) 149-155
6. Friedel, A., Geyer, H., Kamber, M., Laudenbach-Leschowsky, U., Schanzer, W., Thevis, M., Vollmer, G., Zierau, O., Diel, P., 2006. Tetrahydrogestrinone is a potent but unselective binding steroid and affects glucocorticoid signalling in the liver. Toxicol. Lett. 20;164(1):16-23.
7. Geyer H., Parr M.K., Mareck U., Reinhart U., Schrader Y., and Schänzer W. Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids-results of an international study. Int. J. Sports Med. 25 (2004) 124-129
8. Jockenhövel F., Vogel E., Kreutzer M., Reinhardt W., Lederbogen S., and Reinwein D. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin. Endocrinol. (Oxf.) 45 1 (1996) 61-71
9. Kincl F., and Dorfman R. Anabolic-androgenic potency of various steroids in a castrated rat assay. Steroids 3 (1964) 109-122
10. Lévesque J.F., Gaudreault M., Aubin Y., and Chauret N. Discovery, biosynthesis, and structure elucidation of new metabolites of norandrostenedione using in vitro systems. Steroids 70 4 (2005) 305-317
11. Marbury T., Hamill E., Bachand R., Sebree T., and Smith T. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Biopharm. Drug Dispos. 24 3 (2003) 115-120
12. Parr M.K., Geyer H., Reinhart U., and Schanzer W. Analytical strategies for the detection of non-labelled anabolic androgenic steroids in nutritional supplements. Food Addit. Contam. 21 7 (2004) 632-640
13. Sekera M.B., Ahrens B.D., Chang Y.Z., Starcevic B., Georgakopoulos C., and Catlin D.H. Another designer steroid: discovery, synthesis, and detection of 'madol' in urine. Rapid. Commun. Mass Spectrom. 19 6 (2005) 781-784
14. Schnirring L. DHEA: hype, hope not matched by facts. Phys. Sports Med. 26 (1998) 17-22
15. Schrader, Y., Schanzer, W., 2004. Plasma levels of 19-norsteroids after administration of oral and sublingual norandrostendione. Recent advantages in doping analysis. Sport Buch Strauss 12:109-119.
16. Schrader Y., 2007. Quantitative Bestimmung von 19-Norsteroiden nachperoraler und sublingualer Applikation von Norandrostendion und Norandrostendiol. Eine klinische Studie zum Metabolismus von Nandrolon-Prohormonen, Dissertation Deutsche Sporthochschule Köln.
17. Sinnere D., Bachmann M., 2004. Anabole Steroide. Das schwarze Buch. BMS Verlag, Gronau.
18. Takahashi M., Tatsugi Y., and Kohno T. Endocrinological and pathological effects of anabolic-androgenic steroid in male rats. Endocr. J. 51 4 (2004) 425-434
19. Toth M., and Zakar T. Relative binding affinities of testosterone, 19-nortestosterone and their 5 alpha-reduced derivates to the androgen receptor and to other androgen-binding proteins. J. Steroid Biochem. 17 6 (1982) 653-660
20. Uralets V.P., and Gillette P.A. Over-the-counter anabolic steroids 4-androsten-3, 17-dione; 4-androsten-3beta, 17beta-diol; and 19-nor-4-androstene-3,17-dione: excretion studies in men. J. Anal. Toxicol. 23 (1999) 357-366
21. Vanderschueren D., Van Herck E., Suiker A.M., Visser W.J., Schot L.P., and Bouillon R. Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency. Endocrinology 130 5 (1992) 2906-2916
22. Yamasaki K., Sawaki M., Ohta R., Okuda H., Katayama S., Yamada T., Ohta T., Kosaka T., and Owens W. OECD validation of the Hershberger assay in Japan: phase 2 dose response of methyltestosterone, vinclozolin, and p,p'-DDE. Environ Health Perspect. 111 16 (2003) 1912-1919
23. Ziegenfuss T.N., Berardi J.M., and Lowery L.M. Effects of prohormone supplementation in humans: a review. Can. J. Appl. Physiol. 27 6 (2002) 628-646